Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Systematic review with meta-analysis: high mortality in patients with nonsevere alcoholic hepatitis.

Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD.

Aliment Pharmacol Ther. 2019 Jun 23. doi: 10.1111/apt.15376. [Epub ahead of print] Review.

PMID:
31231848
2.

Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R, Hyland R, Lu S, Kirby B, Meng A, Markova S, Dvory-Sobol H, Osinusi AO, Bruck R, Ampuero J, Ryder SD, Agarwal K, Fox R, Shaw D, Haider S, Willems B, Lurie Y, Calleja JL, Gane EJ.

J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30343-5. doi: 10.1016/j.jhep.2019.05.028. [Epub ahead of print]

3.

Ex Vivo T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis.

Dhanda AD, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ, Cramp ME.

Gut Liver. 2019 Jun 3. doi: 10.5009/gnl19035. [Epub ahead of print]

4.

Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population.

Alsaleh M, Barbera TA, Reeves HL, Cramp ME, Ryder S, Gabra H, Nash K, Shen YL, Holmes E, Williams R, Taylor-Robinson SD.

Hepat Med. 2019 May 3;11:47-67. doi: 10.2147/HMER.S193996. eCollection 2019.

5.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
6.

Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R, Cramp ME, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Ferguson J, Foster GR, Gilmore I, Greenberg J, Henn C, Hudson M, Jarvis H, Kelly D, Mann J, McDougall N, McKee M, Moriarty K, Morling J, Newsome P, O'Grady J, Rolfe L, Rice P, Rutter H, Sheron N, Thorburn D, Verne J, Vohra J, Wass J, Yeoman A.

Lancet. 2018 Dec 1;392(10162):2398-2412. doi: 10.1016/S0140-6736(18)32561-3. Epub 2018 Nov 22.

PMID:
30473364
7.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B.

Hepatology. 2018 Jun;67(6):2113-2126. doi: 10.1002/hep.29852. Epub 2018 Apr 19.

PMID:
29473975
8.

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O'Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A.

Lancet. 2018 Mar 17;391(10125):1097-1107. doi: 10.1016/S0140-6736(17)32866-0. Epub 2017 Nov 29. Erratum in: Lancet. 2017 Dec 7;:.

9.

Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.

Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Segal FP, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY.

Sci Rep. 2017 Nov 20;7(1):15843. doi: 10.1038/s41598-017-16011-2.

10.

Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.

Ow MM, Hegazy D, Warshow UM, Cramp ME.

J Viral Hepat. 2018 Mar;25(3):245-253. doi: 10.1111/jvh.12810. Epub 2017 Nov 20.

PMID:
29063663
11.

Lipid interactions influence hepatitis C virus susceptibility and resistance to infection.

Shawa IT, Sheridan DA, Felmlee DJ, Cramp ME.

Clin Liver Dis (Hoboken). 2017 Jul 28;10(1):17-20. doi: 10.1002/cld.643. eCollection 2017 Jul. Review. No abstract available.

12.

Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users.

Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA, Cramp ME.

J Viral Hepat. 2017 Dec;24(12):1082-1088. doi: 10.1111/jvh.12720. Epub 2017 May 30. Review.

PMID:
28475247
13.

Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids.

Dhanda AD, Sinha A, Hunt V, Saleem S, Cramp ME, Collins PL.

World J Gastroenterol. 2017 Mar 21;23(11):2052-2059. doi: 10.3748/wjg.v23.i11.2052.

14.

Hepatorenal syndrome: Update on diagnosis and therapy.

Acevedo JG, Cramp ME.

World J Hepatol. 2017 Feb 28;9(6):293-299. doi: 10.4254/wjh.v9.i6.293.

15.

Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.

Swann RE, Mandalou P, Robinson MW, Ow MM, Foung SK, McLauchlan J, Patel AH, Cramp ME.

J Viral Hepat. 2016 Nov;23(11):873-880. doi: 10.1111/jvh.12568. Epub 2016 Jul 13.

16.

Implementation of the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J, Dyson J, Ferguson J, Foster G, Gilmore SI, Glynn M, Guthrie JA, Hudson M, Kelly D, Langford A, Newsome P, O'Grady J, Pryke R, Ryder S, Samyn M, Sheron N, Verne J.

Lancet. 2015 Nov 21;386(10008):2098-2111. doi: 10.1016/S0140-6736(15)00680-7. Epub 2015 Nov 20. No abstract available.

PMID:
26700394
17.

Diagnosis and management of hepatitis C.

Vine LJ, Sieberhagen C, Cramp ME.

Br J Hosp Med (Lond). 2015 Nov;76(11):625-30. doi: 10.12968/hmed.2015.76.11.625. Review.

PMID:
26551491
18.

Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV.

Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG, Cramp ME.

J Med Virol. 2015 Jul;87(7):1207-17. doi: 10.1002/jmv.24179. Epub 2015 Apr 23.

PMID:
25908236
19.

Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.

Jothimani D, Cramp ME, Cross TJ.

J Clin Exp Hepatol. 2014 Sep;4(3):221-5. doi: 10.1016/j.jceh.2014.05.003. Epub 2014 Jun 24.

20.

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.

J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7.

21.

Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.

Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J.

BMC Gastroenterol. 2014 Aug 7;14:137. doi: 10.1186/1471-230X-14-137.

22.

Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation.

Ow MM, Erasmus P, Minto G, Struthers R, Joseph M, Smith A, Warshow UM, Cramp ME, Cross TJ.

Liver Transpl. 2014 Sep;20(9):1081-8. doi: 10.1002/lt.23907. Epub 2014 Aug 4.

23.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
24.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
25.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
26.

Polymorphic differences in SOD-2 may influence HCV viral clearance.

Houldsworth A, Metzner M, Shaw S, Kaminski E, Demaine AG, Cramp ME.

J Med Virol. 2014 Jun;86(6):941-7. doi: 10.1002/jmv.23923. Epub 2014 Mar 7.

PMID:
24610415
27.

Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, Hydes TJ, Cramp ME, Alexander G, Little AM, Thimme R, Neumann-Haefelin C, Khakoo SI.

Hepatology. 2013 Sep;58(3):881-9. doi: 10.1002/hep.26415. Epub 2013 Jul 29.

28.

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.

Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL.

Ann Intern Med. 2013 Feb 19;158(4):235-45. doi: 10.7326/0003-4819-158-4-201302190-00003.

29.

Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection.

Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S, Cramp ME.

J Viral Hepat. 2012 Jul;19(7):501-8. doi: 10.1111/j.1365-2893.2011.01574.x. Epub 2012 Jan 4.

PMID:
22676363
30.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
31.

Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Thurairajah PH, Hegazy D, Demaine A, Kaminski ER, Cramp ME.

J Infect Dis. 2011 Mar 15;203(6):847-53. doi: 10.1093/infdis/jiq121.

32.

Treatment of autoimmune hepatitis: a review of current and evolving therapies.

Jothimani D, Cramp ME, Mitchell JD, Cross TJ.

J Gastroenterol Hepatol. 2011 Apr;26(4):619-27. doi: 10.1111/j.1440-1746.2010.06579.x. Review.

PMID:
21073674
33.

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.

Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp ME, Khakoo SI.

Hepatology. 2010 Apr;51(4):1168-75. doi: 10.1002/hep.23477.

34.

Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C.

Rashid M, Mitchell JD, Cramp ME, Cross TJ.

Hepatology. 2010 Jan;51(1):354-5. doi: 10.1002/hep.23185. No abstract available.

PMID:
19750544
35.

Elastography for the non-invasive assessment of liver disease: limitations and future developments.

Cross TJ, Mitchell JD, Cramp ME.

Gut. 2009 Aug;58(8):1171-2; author reply 1172. No abstract available.

PMID:
19592700
36.

Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection.

Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV, Cramp ME.

J Infect Dis. 2008 Dec 15;198(12):1749-55. doi: 10.1086/593337.

PMID:
18959498
37.

Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection.

Hegazy D, Thurairajah P, Metzner M, Houldsworth A, Shaw S, Kaminski E, Demaine AG, Cramp ME.

Clin Exp Immunol. 2008 Jun;152(3):538-41. doi: 10.1111/j.1365-2249.2008.03655.x. Epub 2008 Apr 16.

38.

Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression.

Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C, Cramp ME.

Int J STD AIDS. 2006 Jan;17(1):67-9.

PMID:
16409685
39.

Hepatic hydrothorax.

Awasthi AK, Cramp ME.

Br J Hosp Med (Lond). 2005 Sep;66(9):540-1. No abstract available.

PMID:
16200802
40.

Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics.

Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Dalton HR, Harrison TJ, Hill SF, Macfarlane L, Meigh RE, Shafi S, Sheppard MJ, Smithson J, Wilson MP, Teo CG.

J Infect Dis. 2005 Oct 1;192(7):1166-72. Epub 2005 Aug 22.

PMID:
16136458
41.

Polymorphisms in the IL-12B gene and outcome of HCV infection.

Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG, Cramp ME.

J Interferon Cytokine Res. 2005 May;25(5):271-6.

PMID:
15871664
42.

Screening for hepatitis C virus in the Dartmoor prison population: an observational study.

Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME.

J Public Health (Oxf). 2004 Dec;26(4):372-5.

PMID:
15598857
43.

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.

Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M.

Science. 2004 Aug 6;305(5685):872-4.

44.

Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT.

Kyrlagkitsis I, Portmann B, Smith H, O'Grady J, Cramp ME.

Am J Gastroenterol. 2003 Jul;98(7):1588-93.

PMID:
12873583
45.
46.

Investigation and treatment of ascites.

Saravanan R, Cramp ME.

Clin Med (Lond). 2002 Jul-Aug;2(4):310-3. Review. No abstract available.

47.

Re: Whither smooth muscle antibodies in the third millennium?

Katona SJ, Cooper PC, Cramp ME, Kaminski ER.

J Clin Pathol. 2002 Jul;55(7):558-9. No abstract available.

48.

Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center.

Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O'Grady J.

Hepatogastroenterology. 2002 Mar-Apr;49(44):524-8.

PMID:
11995487
49.

Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases.

Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME.

J Hepatol. 2002 Feb;36(2):295-301.

PMID:
11830344
50.

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV.

Gastroenterology. 2000 Feb;118(2):346-55.

PMID:
10648463

Supplemental Content

Loading ...
Support Center